A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer

Neoplasia

Volumn 7, Issue 12, 2005, Pages 1112-1122

  Pinzon Charry, Alberto ^a   Ho, Christopher S K ^b   Laherty, Richard ^a,c   Maxwell, Tammy ^a   Walker, David ^c   Gardiner, Robert A ^c   O'Connor, Linda ^a   Pyke, Christopher ^d   Schmidt, Chris ^a   Furnival, Colin ^e   López, José Alejandro ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d MATER HOSPITAL   (Australia)

^e WESLEY HOSPITAL   (Australia)

Author keywords

Breast cancer; Dendritic cell subsets; Immature antigen presenting cell; Immune dysfunction; Solid tumors

Indexed keywords

CD123 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; HLA DR1 ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; BREAST ADENOCARCINOMA; BREAST METASTASIS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PATIENT; CELL COMPARTMENTALIZATION; CELL POPULATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; T LYMPHOCYTE ACTIVATION; TUMOR RECURRENCE; ADENOCARCINOMA; BLOOD; BREAST TUMOR; CELL PROLIFERATION; COMPARATIVE STUDY; CYTOLOGY; IMMUNOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SECRETION; T LYMPHOCYTE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; BREAST NEOPLASMS; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; GLIOMA; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; MYELOID CELLS; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 33644877326     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05442     Document Type: Article

References (43)

1. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, and Palucka K (2000). Immunobiology of dendritic cells. Annu Rev Immunol 18, 767-811.
2. Fong L and Engleman EG (2000). Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18, 245-273.
3. + T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 6, 1351-1364.
4. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942-949.
5. Pekarek LA, Starr BA, Toledano AY, and Schreiber H (1995). Inhibition of tumor growth by elimination of granulocytes. J Exp Med 181, 435-440.
6. Enk AH, Jonuleit H, Saloga J, and Knop J (1997). Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73, 309-316.
7. Troy AJ, Davidson PJ, Atkinson CH, and Hart DN (1999). CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J Urol 161, 1962-1967.
8. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, and Carbone DP (1997). Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3, 483-490.
9. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, and Banchereau J (1999). In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190, 1417-1426.
10. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, and Hart DN (1998). Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 4, 585-593.
11. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, and Gabrilovich DI (2000). Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6, 1755-1766.
12. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, and Carbone DP (1996). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2, 1096-1103.
13. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, et al. (2002). Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100, 230-237.
14. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, and Blay JY (1998). Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92, 4778-4791.
15. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, Pinedo HM, van den Eertwegh AJ, Scheper RJ, and de Gruijl TD (2002). Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 168, 4333-4343.
16. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M, and Villa ML (2003). Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89, 1463-1472.
17. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, and Carbone DP (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150-4166.
18. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, and Barksdale EM Jr (2001). Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61, 363-369.
19. Lissoni P, Vigore L, Ferranti R, Bukovec R, Meregalli S, Mandala M, Barni S, Tancini G, Fumagalli L, and Giani L (1999). Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J Biol Regul Homeost Agents 13, 216-219.
20. Hoffmann TK, Muller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ, and Whiteside TL (2002). Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8, 1787-1793.
21. Pinzon-Charry A, Maxwell T, and Lopez JA (2005). Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83, 451-467.
22. Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, Valerio D, and Eremin O (2004). Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 53, 510-518.
23. Savary CA, Grazziutti ML, Melichar B, Przepiorka D, Freedman RS, Cowart RE, Cohen DM, Anaissie EJ, Woodside DG, McIntyre BW, et al. (1998). Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother 45, 234-240.
24. Robinson SP, Patterson S, English N, Davies D, Knight SC, and Reid CD (1999). Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 29, 2769-2778.
25. Sobin LH and Wittekind C (2002). International Union Against Cancer: TNM Classification of Malignant Tumors. Wiley-Liss, New York.
26. Kleihues P and Cavenee WK (2000). World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System. IARC Press, Lyon, France.
27. Lee AW, Truong T, Bickham K, Fonteneau JF, Larsson M, Da Silva I, Somersan S, Thomas EK, and Bhardwaj N (2002). A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20, A8-A22.
28. Krug A, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, Sarris A, Giese T, Speiser D, Endres S, et al. (2003). CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J Immunol 170, 3468-3477.
29. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, and Lanzavecchia A (1999). Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 189, 821-829.
30. Schuster H, Jellinger K, Gund A, and Regele H (1976). Extracranial metastases of anaplastic cerebral gliomas. Acta Neurochir (Wien) 35, 247-259.
31. Sallusto F, Cella M, Danieli C, and Lanzavecchia A (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182, 389-400.
32. Jefford M, Schnurr M, Toy T, Masterman KA, Shin A, Beecroft T, Tai TY, Davis ID, Shackleton M, Davis ID, et al. (2003). Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood 102, 1753-1763.
33. MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, and Hart DN (2002). Characterization of human blood dendritic cell subsets. Blood 100, 4512-4520.
34. Kanto T, Kalinski P, Hunter OC, Lotze MT, and Amoscato A (2001). Ceramide mediates tumor-induced dendritic cell apoptosis. J Immunol 167, 3773-3784.
35. Kiertscher SM, Luo J, Dubinett SM, and Roth MD (2000). Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164, 1269-1276.
36. + cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer 73, 663-669.
37. + natural suppressor cells. Int J Cancer 74, 69-74.
38. Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, Jove R, and Gabrilovich D (2004). Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 172, 464-474.
39. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, and Gabrilovich DI (1998). Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 160, 1224-1232.
40. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, and Gabrilovich DI (2001). Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166, 678-689.
41. Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, and Young MR (1995). Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1, 95-103.
42. Esche C, Gambotto A, Satoh Y, Gerein V, Robbins PD, Watkins SC, Lotze MT, and Shurin MR (1999). CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol 29, 2148-2155.
43. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, and Levy R (1999). Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 93, 2411-2419.